Skip to main content


Figure 1 | Journal of Translational Medicine

Figure 1

From: Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort

Figure 1

Kaplan–Meier curves for PFS and OS. PFS for all patients (A). OS for all patients (B). OS for BRAF-mutation positive (n = 173) and BRAF wildtype (n = 296) patients (C). OS for NRAS-mutation positive (n = 14) and NRAS wildtype (n = 68) patients (D). OS in patients with or without an irAE (any grade) in patients with who received three or four cycles of ipilimumab (E). PFS: progression-free survival; OS: overall survival; irAE: immune-related adverse event.

Back to article page